Back to Search
Start Over
An unfavourable outcome following switching intravenous abatacept and tocilizumab to subcutaneous forms during the COVID-19 pandemic
- Source :
- Rheumatology (Oxford, England), Rheumatology
- Publication Year :
- 2020
- Publisher :
- Oxford University Press, 2020.
- Subjects :
- medicine.medical_specialty
2019-20 coronavirus outbreak
Coronavirus disease 2019 (COVID-19)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Injections, Subcutaneous
MEDLINE
Self Administration
Antibodies, Monoclonal, Humanized
Abatacept
Arthritis, Rheumatoid
chemistry.chemical_compound
Tocilizumab
Rheumatology
Internal medicine
Pandemic
medicine
Humans
Pharmacology (medical)
Infusions, Intravenous
AcademicSubjects/MED00360
business.industry
Drug Substitution
SARS-CoV-2
COVID-19
Patient Preference
Treatment Outcome
chemistry
Letter to the Editor (Other)
Antirheumatic Agents
Disease Progression
business
Decision Making, Shared
medicine.drug
Subjects
Details
- Language :
- English
- ISSN :
- 14620332 and 14620324
- Database :
- OpenAIRE
- Journal :
- Rheumatology (Oxford, England)
- Accession number :
- edsair.doi.dedup.....b4d25f3bcb94845a7e3a9e4a62a06eaa